Health Care/Hospital News & Press Release Distribution

BGI Genomics Launches "Digital Life Twin" Framework to Power Proactive Health

SHENZHEN, China, Sept. 9, 2026 /PRNewswire/ -- Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-s...

2026-09-09 21:45 1601

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA form...

2026-09-09 21:00 3323

Clinical Psychologist Urges Women to Recognise the Signs of a Dysregulated Nervous System

MELBOURNE, Australia, Sept. 9, 2026 /PRNewswire/ -- Women are becoming increasingly skilled at functioning while struggling, says Clinical Psychologist Dr Jennifer Menon, who is urging women to recognise signs of prolonged stress and trauma before reaching breaking point.

2026-09-09 20:56 1345

Clinical Psychologist Urges Women to Recognise the Signs of a Dysregulated Nervous System

Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-09-09 20:56 2000

Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...

2026-09-09 20:25 1635

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...

2026-09-09 20:00 1331

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited

2026-09-09 19:30 1135

Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...

2026-09-09 19:12 1352

Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026

Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc....

2026-09-09 18:30 938

Abbott and Sengkang General Hospital expand partnership to advance early detection of muscle loss and support healthy aging

* The expanded three-year collaboration will integrate muscle health screenings into hospital and community settings, train healthcare professionals, and increase public education * Since launching in 2023, the partnership has trained nearly 300 healthcare professionals to assess muscle healt...

2026-09-09 18:10 1307

Abbott and Sengkang General Hospital expand partnership to advance early detection of muscle loss and support healthy aging

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...

2026-09-09 18:00 1177

Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize

Joint research team modeled a 12,635-atom protein, the largest-known to be simulated using quantum computers. Breakthrough was achieved through quantum and classical methods working together, expanding quantum-centric supercomputing's potential in life sciences research. CLEVELAND and WAKO, Jap...

2026-09-09 12:00 1257

Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation

SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded nutraceutical solution platform into the growing sleep wellness category with the introduction of NF TriSolve® SleepRestore ...

2026-09-08 22:00 2180

Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation

Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026

Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...

2026-09-08 21:00 1652

Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026

GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- GROWNSY, a baby care brand trusted by more than 3 million households worldwide, today announced a new long-term partnership with Graham's Foundation, a nonprofit organization dedicated to supporting parents of premature babies. The partnership will begin d...

2026-09-08 21:00 1349

GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay

Metabolon Verus™ Metabolomics Profiling Kit Now Available to Order

A successful multi-site ring trial and early access program demonstrate the reproducibility, scalability, and biological insight of the Metabolon Verus™ Metabolomics Profiling Kit across laboratories worldwide MORRISVILLE, N.C., Sept. 8, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in...

2026-09-08 21:00 1086

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...

2026-09-08 20:20 1261

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...

2026-09-08 20:17 1414

Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy

SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational ...

2026-09-08 20:15 1268

Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * SKB378/WIN378 produce...

2026-09-08 20:02 1351